Neuroscience Advances: Stem Cell Therapies and Migraine Innovations

This week in neuroscience: Sanofi acquires Vigil Neuroscience for $470 million, advancing VG-3927 for Alzheimer’s by activating microglia via TREM2. The EMA grants orphan drug status to BioArctic’s Exidavnemab for multiple system atrophy. CureDuchenne invests $1 million in Entos Pharmaceuticals for a redosable dystrophin gene therapy in Duchenne muscular dystrophy. UniXell begins Phase 1 trial of iPSC-derived therapy UX-DA001 for Parkinson’s in China. China approves the first allogeneic iPSC therapy for spinal cord injury. Salvia BioElectronics raises €53 million for its migraine implant, MySalvia Therapy.

Видео Neuroscience Advances: Stem Cell Therapies and Migraine Innovations канала LucidQuest